

TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS₉

Tech ID: 25143 / UC Case 2015-205-0

PATENT STATUS

Country	Type	Number	Dated	Case
Japan	Issued Patent	7268103	04/24/2023	2015-205
United States Of America	Issued Patent	10,851,367	12/01/2020	2015-205
Japan	Published Application	P2018-537448A	12/20/2018	2015-205
European Patent Office	Published Application	3 373 979	09/19/2018	2015-205
Argentina	Published Application	AR 106639 A1	02/07/2018	2015-205

Additional Patents Pending

BRIEF DESCRIPTION

Delivering gene-editing agents safely and effectively has long been a challenge in modern medicine. Traditional methods using viral vectors introduce risks such as insertional mutagenesis, hepatotoxicity, and transient therapeutic effects due to immune responses. UC Berkeley researchers have developed a groundbreaking tissue-specific genome engineering system utilizing CRISPR-Cas9, offering a safer and more precise alternative for gene therapy.

UC Berkeley researchers and others have created compounds, compositions, uses thereof the combines the cutting-edge CRISPR technology with advanced targeting mechanisms for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

SUGGESTED USES

- » Gene editing
- » Gene delivery

ADVANTAGES

- » By leveraging ASGPR targeting agents, this approach ensures precise uptake by hepatocytes and other specific tissues.
- » Avoids the risks associated with viral vectors, reducing toxicity and immune complications.
- » By delivering gene-editing agents in protein form rather than DNA or RNA, the technology maximizes therapeutic potential while minimizing unwanted genetic disruptions.
- » Overcomes the limitations of receptor-mediated endocytosis to ensure the therapeutic agents effectively reach their intended subcellular locations.

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS
- ▶ Genome Editing via LNP-Based Delivery of Efficient and Stable CRISPR-Cas Editors
- ▶ Type III CRISPR-Cas System for Robust RNA Knockdown and Imaging in Eukaryotes
- ▶ Cas9 Variants With Altered DNA Cleaving Activity

CONTACT

Terri Sale
terri.sale@berkeley.edu
tel: 510-643-4219.



INVENTORS

- » Doudna, Jennifer A.

OTHER INFORMATION

CATEGORIZED AS

- » **Medical**
- » Gene Therapy
- » Research Tools
- » Therapeutics

RELATED CASES

2015-205-0

- ▶ Cas12-mediated DNA Detection Reporter Molecules
- ▶ Improved guide RNA and Protein Design for CasX-based Gene Editing Platform
- ▶ Cas13a/C2c2 - A Dual Function Programmable RNA Endoribonuclease
- ▶ Miniature Type VI CRISPR-Cas Systems and Methods of Use
- ▶ RNA-directed Cleavage and Modification of DNA using CasY (CRISPR-CasY)
- ▶ Generation of Chimeric RNA with Type III CRISPR-Cas
- ▶ CasX Nickase Designs, Tans Cleavage Designs & Structure
- ▶ In Vivo Gene Editing Of Tau Locus Via Liponanoparticle Delivery
- ▶ Methods and Compositions for Modifying a single stranded Target Nucleic Acid
- ▶ A Dual-RNA Guided CasZ Gene Editing Technology
- ▶ A Protein Inhibitor Of Cas9
- ▶ RNA-directed Cleavage and Modification of DNA using CasX (CRISPR-CasX)
- ▶ Compositions and Methods for Genome Editing
- ▶ IS110 and IS1111 Family RNA-Guided Transposons
- ▶ Variant Cas12a Protein Compositions and Methods of Use
- ▶ In Vitro and In Vivo Genome Editing by LNP Delivery of CRISPR Ribonucleoprotein
- ▶ CRISPR CASY COMPOSITIONS AND METHODS OF USE
- ▶ Single Conjugative Vector for Genome Editing by RNA-guided Transposition
- ▶ Improved Cas12a Proteins for Accurate and Efficient Genome Editing
- ▶ CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
- ▶ Methods Of Use Of Cas12L/CasLambda In Plants
- ▶ Type V CRISPR/CAS Effector Proteins for Cleaving ssDNA and Detecting Target DNA
- ▶ THERMOSTABLE RNA-GUIDED ENDONUCLEASES AND METHODS OF USE THEREOF (GeoCas9)
- ▶ Variant TnpB and wRNA Proteins
- ▶ Efficient Site-Specific Integration Of New Genetic Information Into Human Cells
- ▶ Class 2 CRISPR/Cas COMPOSITIONS AND METHODS OF USE
- ▶ Compositions and Methods of Use for Variant Csy4 Endoribonucleases
- ▶ Immune Cell-Mediated Intercellular Delivery Of Biomolecules
- ▶ Methods and Compositions for Controlling Gene Expression by RNA Processing



University of California, Berkeley Office of Technology Licensing

2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704

Tel: 510.643.7201 | Fax: 510.642.4566

<https://ipira.berkeley.edu/> | otl-feedback@lists.berkeley.edu

© 2025, The Regents of the University of California

[Terms of use](#) | [Privacy Notice](#)